In December 2024, MIS Healthcare, a leading specialist provider of medical equipment and radiopharmaceuticals in the UK and Ireland, completed the acquisition of Xiel. Xiel is focussed on radiotherapy and nuclear medicine and the acquisition will enhance MIS’s market position in this specialist high-growth sector.
Xiel (www.xiel.co.uk) was founded in 2019 and comes with a strong portfolio of products, high-quality operations and an ambitious management team to support MIS’s future growth ambitions.
The acquisition adds further scale to MIS, with the group now generating over £50 million revenue, and supports its strategy of becoming a leading diagnostic imaging service and equipment solutions provider with specialist oncology and radiotherapy capabilities.
For further information on MIS Healthcare, please visit: www.mishealthcare.co.uk
About H2 Equity Partners
H2 Equity Partners is a leading independent investment firm, making investments in medium-sized companies with significant growth or improvement potential. The H2 team has built an exceptional track record of acquiring, strengthening and growing fundamentally attractive businesses. H2 invests in companies across all sectors, that have strong market positions and competitive advantages, which can benefit from the extensive international operating experience of the H2 team.H2 Equity Partners Fund VI was launched in July 2022 and focuses on making investments in the United Kingdom and Ireland.
